Longeveron price target lowered to $2 from $3 at Roth Capital

Roth Capital lowered the firm’s price target on Longeveron (LGVN) to $2 from $3 but keeps a Buy rating on the shares. The firm continues to expect top-line data from the ELPIS II study evaluating Laromestrocel in HLHS – hypoplastic left heart syndrome – patients in Q3 of this year, and if positive, a BLA filing is expected to occur in 2027, the analyst tells investors in a research note.